Recent studies have shown that the combined use of EGFR TK inhibitors and c-Met inhibitors can effectively inhibit the growth of multiple tumor cells significantly better than either alone [23], thus necessitating the design and synthesis of multi-target inhibitors targeting EGFR and c-Met to develop highly effective, low toxicity, multi-target anti-tumor inhibitors. The gene discussed is EGFR; the disease is neoplasm.